Anti-CDKN2A/p19ARF 抗体 (ab80)
製品の概要
-
製品名Anti-CDKN2A/p19ARF antibody
CDKN2A/p19ARF 一次抗体 製品一覧 -
製品の詳細Rabbit polyclonal to CDKN2A/p19ARF
-
由来種Rabbit
-
特異性On Western blot the antibody reveals IVT murine p19ARF and a band of the same size in CTLL2 cells. It detects a specific band in WT mouse embryo fibroblasts which is not present in p19ARF-null MEFs.
-
アプリケーション適用あり: ICC/IF, ICC, ELISA, IHC-P, WB, IHC-Frmore details
-
種交差性交差種: Mouse
非交差種: Rat, Human -
免疫原
Synthetic peptide conjugated to KLH derived from within residues 50 - 150 of Mouse p19ARF.
Immunogen の所有権に関して (Peptide available as ab2659.) -
ポジティブ･コントロール
- mouse embryonic fibroblasts lysate
-
特記事項The blocking peptide for this antibody is available (ab2659)
製品の特性
-
製品の状態Liquid
-
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
バッファーpH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading... -
精製度Immunogen affinity purified
-
特記事項（精製）The serum has been purified on a peptide-NHS-activated Sepharose column. Specific antibodies have been eluted with 100 mM glycine pH 2.5. The purified antibodies have been dialysed against PBS pH 7.4.
-
ポリ/モノポリクローナル
-
アイソタイプIgG
-
研究分野
関連製品
-
Compatible Secondaries
アプリケーション
Our Abpromise guarantee covers the use of ab80 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| ICC/IF | 1/250. | |
| ICC | Use a concentration of 1 µg/ml. Fix with a 1:1 mixture of methanol:acetone at -20C for 10 mins (see image by Dr. David Bertwistle). | |
| ELISA | Use at an assay dependent concentration. | |
| IHC-P | Use a concentration of 1 µg/ml. PubMed: 11726500 | |
| WB | 1/1000. Detects a band of approximately 19 kDa (predicted molecular weight: 17 kDa). Multiple bands with this antibody have frequently been reported. We believe that this is due to the different modification states of p19ARF. Nuclear extraction may be necessary in some samples. | |
| IHC-Fr | 1/100. |
ターゲット情報
-
関連性The gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.
-
細胞内局在Nuclear
-
参照データベース
- Entrez Gene: 12578 Mouse
- SwissProt: Q64364 Mouse
- Unigene: 4733 Mouse
-
別名
- ARF antibody
- CDKN2A antibody
- Cyclin dependent kinase inhibitor 2A antibody
see all
画像
-
Western blot - Anti-CDKN2A/p19ARF antibody (ab80)This image is courtesy of Charles SherrAll lanes : Anti-CDKN2A/p19ARF antibody (ab80) at 1 µg/ml
Lanes 1-2 : 30 ug of mouse embryonic fibroblast total cell extract.
Lane 3 : 30 ug of mouse embryonic fibroblast total cell extract, with the p19ARF gene knocked out as a negative control.
Performed under reducing conditions.
Predicted band size: 17 kDa
Observed band size: 19 kDa why is the actual band size different from the predicted?Western blot of primary Mouse Embryo Fibroplasts (MEFs) using ab80 at 1
µ g/ml. (30µ g of protein from total cell extracts per lane.) -
Immunocytochemistry - Anti-CDKN2A/p19ARF antibody (ab80)Pictures were generously provided by Dr. David Bertwistleab80 antibody was tested on NIH 3T3 cells (which have a deletion of the p19ARF gene) as a negative control (-) and NIH 3T3 cells engineered to express HA-tagged p19ARF as a positive control (+).
Cells grown on coverslips were fixed with a 1:1 mixture of methanol:acetone at -20C for 10 mins. After drying, rehydrating and blocking, the co
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDKN2A/p19ARF antibody (ab80)This image is courtesy of an anonymous Abreviewab80 at 1/300 staining mouse kidney (glomerulus) tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 45 minutes. An HRP conjugated goat anti-rabbit antibody was used as the secondary. -
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p19ARF antibody (ab80)This image is courtesy of an Abreview submitted by Mrs Nanna Forsbergab80 at 1/300 staining mouse brain cells by ICC/IF.
Paraformaldehyde fixation, Triton X-100 permeabilization, followed by blocking with 3% BSA + 2% NGS for 1 hour at 20°C.
Incubation with the primary antibody was carried out for 1 hour at 20°C. The secondary antibody was an Alexa Fluor® conjugated Donkey anti-Rabbit polyclonal, diluted 1/400.
-
Immunohistochemistry (Frozen sections) - Anti-CDKN2A/p19ARF antibody (ab80)This image is courtesy of an anonymous Abreviewab80 staining CDKN2A/p19ARF in Mouse pancreatic neoplastic tissue sections by Immunohistochemistry (IHC-Fr - frozen sections). Tissue was fixed with paraformaldehyde and blocked with 5% serum for 1 hour at room temperature. Samples were incubated with primary antibody (1/100 in PBS) for 8 hours at 4°C. An Alexa Fluor®555-conjugated Donkey anti-rabbit IgG polyclonal (1/500) was used as the secondary antibody. Nuclei were stained by DAPI.
データシートおよび資料
プロトコール
参考文献
This product has been referenced in:
- Oldrini B et al. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun 9:1466 (2018). Read more (PubMed: 29654229) »
- Francis JC et al. SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. Oncotarget 9:7604-7615 (2018). Read more (PubMed: 29484136) »
